To make an informed decision about weight loss medications, its helpful to understand how compounded semaglutide compares to other available options, including both FDA-approved and compounded alternatives
It is important to note that Wegovy will remain available for eligible Medicare beneficiaries for other FDA-approved indications through their normal Part D benefits, including to reduce the risk of major adverse cardiovascular events in adults with established CV disease with either obesity or overweight
We have also introduced Ascendis Employeeship, a training initiative designed to help employees take ownership of their work situation and strengthen cross-organizational collaboration
These data suggest that while markers of fibrosis and autophagy are increased following liver-specific Gclc deletion, these are potentially due to the activation of NRF2
46 Based on a lack of robust data regarding the safety and efficacy of simultaneous use of DPP-4 inhibitors and GLP-1 agonists, the combination is not recommended
These symptoms may indicate retinal detachment or other serious conditions unrelated to GLP-1 medication